Article

Countdown to a possible new drug approval for kidney cancer

Author(s):

Melissa Weber

Just got word from a Genentech spokesperson that the company expects to hear by the end of this week whether the FDA will approve Avastin for metastatic kidney cancer. (Check out the kidney cancer feature in our current issue.)We'll keep you posted.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
Image of woman with text.
Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun.
Six-time cancer survivor Staci Kirk urges patients to trust their bodies and speak up to ensure their needs are understood and addressed throughout cancer care.
Clinical trials should be designed to ease travel and financial burdens by using local care, telehealth and remote tools, Kimberly Demirhan explained.
Certain treatments may accelerate aging in survivors, but tailored care and healthy habits can help reduce long-term risks, researchers said.
Image of man with text.
Image of woman with text.
Related Content
Image of man with text.
August 1st 2025

Understanding Epithelioid Hemangioendothelioma: A Rare Vascular Cancer

Gina Mauro
Dr. Michael Wagner covers the basics of epithelioid hemangioendothelioma, a rare vascular cancer, spanning symptoms, diagnosis, treatment options and more.
The Importance of Spotting Endometrial Cancer
August 1st 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
FDA sign.
August 1st 2025

Oncolytic Virus Wins FDA Fast Track Designation in Soft Tissue Sarcoma

Ryan Scott
The U.S. FDA has granted fast track designation to treatment with CLD-201, an oncolytic virus, for patients with soft tissue sarcoma.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
August 1st 2025

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
A resilience program for young people with advanced cancer helped patients cope and led to a better quality of life: © stock.adobe.com.
August 1st 2025

How Resilience Coaching May Help Young People With Advanced Cancer

Spencer Feldman
A resilience program for young people with advanced cancer helped patients cope early on and led to a better quality of life after 6 to 12 months.
Image of kidneys.
August 1st 2025

July GU Cancer Highlights: Top 5 Updates Patients Should Know

Ryan Scott
As July concludes, new treatments offer advances across kidney and bladder cancer, with breakthroughs in personalized vaccines and non-surgical therapies.